Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009348 | 0.88 | GRM5 (0.54) | GRM5TSHRHTR2CHTR2BCYP1A2 | |
| SCHEMBL2013482 | 0.88 | GRM5 (0.60) | GRM5TSHRCYP1A2 | |
| SCHEMBL2013553 | 0.86 | GRM5 (0.48) | GRM5TSHRHTR2CHTR2BCYP1A2 | |
| SCHEMBL2010190 | 0.81 | TSHR (0.50) | GRM5TSHRALDH1A1HTR2CHTR2B | |
| Trifluoroacetic Acid SCHEMBL2010260 | 0.80 | GRM5 (0.50) | GRM5TSHRCYP1A2 | |
| SCHEMBL2010940 | 0.79 | GRM5 (0.62) | GRM5TSHRHTR2CHTR2BCYP1A2 | |
| SCHEMBL2012435 | 0.77 | GRM5 (0.47) | GRM5TSHRRIPK3CYP1A2 | |
| SCHEMBL2014419 | 0.76 | GRM5 (0.53) | GRM5TSHRHTR2CHTR2BCYP1A2 | |
| SCHEMBL30796732 | 0.76 | GRM5 (0.53) | GRM5TSHRHTR2CHTR2BCYP1A2 | |
| Trifluoroacetic Acid SCHEMBL2015764 | 0.73 | GRM5 (0.56) | GRM5TSHRHTR2CHTR2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040707-B2 | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | claimed |
| EP-2513117-B1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-28 | — | — | EP | claimed |
| EP-2513117-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | claimed |
| US-20120258955-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-11 | — | — | US | claimed |
| WO-2011073339-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-9040707-B2 | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | disclosed |
| EP-2513117-B1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-28 | — | — | EP | disclosed |
| EP-2513117-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120258955-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-11 | — | — | US | disclosed |
| WO-2011073339-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258955-A1 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM2 | GRM5 1/4885TSHR 303/4885HPGD 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.